Clinical Trials

3,680 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT06467357 2026-04-16

DESTINY-BTC01

620 enrolled

Biliary Tract Neoplasms

NCT06746116 2026-04-16

DUoENDE

45 enrolled

Gynecologic

Endometrial Neoplasms

NCT07005128 2026-04-16

DeLLphi-312

330 enrolled

Small Cell Lung Carcinoma

NCT03778957 2026-04-15

EMERALD-1

724 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03528694 2026-04-14

POTOMAC

1,018 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04960709 2026-04-14

VOLGA

712 enrolled

Urinary Bladder Neoplasms

NCT06498635 2026-04-14

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

306 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04092283 2026-04-13

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

660 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06732401 2026-04-13

CLEAR

630 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07166406 2026-04-08

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

226 enrolled

Carcinoma, Hepatocellular

NCT07195695 2026-04-08

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05301842 2026-04-07

EMERALD-3

760 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT07361497 2026-04-06

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

850 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05624996 2026-04-03

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

474 enrolled

Lung Neoplasms

NCT06112379 2026-04-02

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

1,902 enrolled

Breast Neoplasms

NCT06103864 2026-03-31

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

625 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06960577 2026-03-30

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

150 enrolled

Urinary Bladder Neoplasms

NCT05771480 2026-03-25

TOURMALINE

142 enrolled

Biliary Tract Neoplasms

NCT06992609 2026-03-25

ALBORAN

70 enrolled

Phase 3 Enrolling by invitation

Small Cell Lung Carcinoma

NCT05303532 2026-03-24

ROSY-D

214 enrolled

Tumor-Agnostic

Neoplasms

NCT06282575 2026-03-24

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

286 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06890598 2026-03-24

SUNRAY-02

700 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03298451 2026-03-20

HIMALAYA

1,324 enrolled 31 charts 2 FDA

Carcinoma, Hepatocellular

NCT04637594 2026-03-20

IMAGINE

3 enrolled 6 charts

Carcinoma, Transitional Cell

NCT03875235 2026-03-19

TOPAZ-1

810 enrolled 24 charts 2 FDA

Biliary Tract Neoplasms

NCT05629585 2026-03-18

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

1,174 enrolled

Breast Neoplasms

NCT07221253 2026-03-17

AB02

1,100 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

NCT03164616 2026-03-13

POSEIDON

1,186 enrolled 26 charts 2 FDA

Non Small Cell Lung Cancer NSCLC

NCT03732677 2026-03-13

NIAGARA

1,063 enrolled 15 charts 3 FDA

Urinary Bladder Neoplasms

NCT05687266 2026-03-13

AVANZAR

1,350 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03003962 2026-03-11

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

669 enrolled 54 charts

Non Small Cell Lung Carcinoma NSCLC

NCT05943106 2026-03-11

PATAPSCO

100 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT03847428 2026-03-06

EMERALD-2

908 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05170204 2026-03-06

HORIZON 1

71 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02453282 2026-03-02

MYSTIC

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT03706690 2026-03-02

PACIFIC-5

407 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT05211895 2026-02-23

PACIFIC-8

860 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05883644 2026-02-18

SIERRA

111 enrolled

Liver Neoplasms

NCT03682068 2026-02-03

NILE

1,246 enrolled

Urinary Bladder Neoplasms

NCT04550260 2026-01-29

KUNLUN

640 enrolled

Esophageal Squamous Cell Carcinoma

NCT02516241 2026-01-28

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

1,126 enrolled 52 charts

Urothelial Cancer

NCT07229625 2026-01-28

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

604 enrolled

Advanced Biliary Tract Cancer

NCT05221840 2026-01-27

PACIFIC-9

1,051 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03833154 2026-01-26

PACIFIC-4

724 enrolled

Other solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04334759 2026-01-22

DREAM3R

Phase 3 Completed

214 enrolled

Mesothelioma, Malignant, Mesothelioma

NCT06591520 2026-01-21

AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer

682 enrolled